Company intelligence / Profile preview

Kivu Bioscience

San Francisco, CA, United Stateskivubioscience.com ↗
Ownership
Private
Development stage
Preclinical
01

Overview

Kivu Bioscience is advancing a pipeline of next-generation antibody-drug conjugates using proprietary site-specific conjugation technologies designed to improve the stability, homogeneity, and therapeutic window of ADC therapies. Their approach aims to reduce off-target toxicity and address limitations seen with current marketed ADCs. The company has raised $92 million Series A financing led by Novo Holdings to bring its first two lead candidates into clinical trials starting in 2025. Early data suggest superior construct stability compared to prior generations.

Therapeutic areas
OncologyOther
Modalities
Antibody-drug conjugates (ADCs)Topo1i-based ADCs (topoisomerase I inhibitor payloads)
Industry
Biotech
02

Drug pipeline

4 assets

KIVU-305

1

3 more assets in the full pipeline.

Request access →
03

Partnerships

Synaffix/Lonza – licensing agreement for GlycoConnect™ site-specific conjugation platform used as core enabling technology for their proprietary linker-payload system.

Beyond the preview

Go deeper on Kivu Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kivu Bioscience.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call